IMR Press / FBL / Volume 12 / Issue 4 / DOI: 10.2741/2147

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Buprenorphine in long-term control of chronic pain in cancer patients
Show Less
1 Department of Anesthesiology, Surgical and Emergency Sciences, Second University of Naples, Naples, Italy
2 Department of Plastic and Reconstructive Surgery, Second University of Naples, Naples, Italy
Front. Biosci. (Landmark Ed) 2007, 12(4), 1291–1299;
Published: 1 January 2007

The aim of this randomized open-label prospective study was to evaluate the analgesic activity of buprenorphine in a transdermal formulation for cancer chronic pain control versus sustained-release morphine, in all cases combined with oral tramadol. A transdermal system with 35 µg/h buprenorphine was applied to the first group of patients (BT); the second group received 60 mg/day of sustained-release morphine (MT). In both groups oral tramadol was administered to a maximum of 200 mg daily, in case of need. The administration of transdermal buprenorphine versus morphine resulted in significant differences in the physical pain (P = 0.01), mental health (P = 0.03) and vitality (P = 0.001). These data indicated that the BT group showed an improvement of pain and a positive effect on the quality life.

Back to top